Compare CRDF & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | PLCE |
|---|---|---|
| Founded | 1999 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 72.5M |
| IPO Year | 2012 | 1997 |
| Metric | CRDF | PLCE |
|---|---|---|
| Price | $0.85 | $2.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.63 | $3.50 |
| AVG Volume (30 Days) | ★ 1.6M | 258.1K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | 11.48 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $0.76 | $2.29 |
| 52 Week High | $3.31 | $9.56 |
| Indicator | CRDF | PLCE |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 32.91 |
| Support Level | N/A | N/A |
| Resistance Level | $2.03 | $3.81 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 7.93 | 15.85 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.